American Association for Cancer Research

sorry, we can't preview this file

crc-22-0385-s01.docx (25.5 kB)

Supplemental Table 1 from Treatment Patterns and Outcomes of Pre-operative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer

Download (25.5 kB)
journal contribution
posted on 2023-04-04, 02:22 authored by Jasleen K Badesha, Marilyn Zhou, Arif A Arif, Sharlene Gill, Caroline Speers, Michael Peacock, Mary A De Vera, Heather C Stuart, Carl J Brown, Fergal Donellan, Jonathan M Loree

Supplemental Table 1 – Characteristics and treatment response in rectal cancers treated with neoadjuvant therapy.



Pre-operative radiotherapy for early-stage rectal cancer has risks and benefits that may impact treatment choice in young patients. We reviewed radiotherapy use and outcomes for rectal cancer by age. Patients with early-stage rectal cancer in the Canadian province of British Columbia from 2002-2016 were identified (n=6232). Baseline characteristics, treatment response, overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and locoregional recurrence rate (LRR) were compared between patients <50 (early-onset) (n=532) and ≥50 years old (average-onset) (n=5700). Early-onset patients were more likely to receive pre-operative chemoradiotherapy than short-course radiotherapy (OR: 2.20, 95% CI: 1.67-2.89, P<0.0001), but also had higher nodal (P=0.00096) and overall clinical staging (P=0.033). Cancer downstaging and pCR rates were similar in those receiving neoadjuvant chemoradiotherapy by age. Early-onset and average-onset patients had similar DSS (P=0.91) and DFS (P=0.27) in multivariate analysis unless non-colorectal deaths, which were higher in older patients, were censored in the DFS model (HR: 1.30, 95% CI: 1.01-1.68, P=0.042). LRR also did not differ between age groups (P=0.88). Outcomes did not differ based on radiotherapy type. Young patients with rectal cancer are more likely to present with higher staging and receive long-course chemoradiotherapy. DSS did not differ by age group, however young patients had worse DFS when we censored competing risks of death in older patients.

Usage metrics

    Cancer Research Communications



    Ref. manager